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 Abstract 26 
Purpose: To provide a means for calibrating raw acceleration data from wrist-worn 27 
accelerometers in relation to past estimates of children’s moderate-to-vigorous 28 
physical activity (MVPA) from a range of cut-points applied to hip-worn ActiGraph 29 
data. Methods: This is a secondary analysis of three studies with concurrent 7-day 30 
accelerometer wear at the wrist (GENEActiv) and hip (ActiGraph) in 238 children 31 
aged 9-12 years. The time spent above acceleration (ENMO) thresholds of 100, 150, 32 
200, 250, 300, 350 and 400 mg from wrist acceleration data (<5 s epoch) was 33 
calculated for comparison to MVPA estimated from widely used children’s hip-worn 34 
ActiGraph MVPA cut-points (Freedson/Trost 1100 counts per minute (cpm); Pate 35 
1680 cpm; Evenson 2296 cpm; Puyau 3200 cpm) with epochs of <5, 15 and 60 s. 36 
Results: The optimal ENMO thresholds for alignment with MVPA estimates from 37 
ActiGraph cut-points determined from 70% of the sample and cross-validated with 38 
the remaining 30% were: Freedson/Trost = ENMO 150+ mg, irrespective of 39 
ActiGraph epoch (ICC>0.65); Pate = ENMO 200+ mg, irrespective of ActiGraph 40 
epoch (ICC>0.67); Evenson = ENMO 250+ mg for <5 s and 15 s epochs (ICC>0.69) 41 
and ENMO 300+ mg for 60 s epochs (ICC=0.73); Puyau = ENMO 300+ mg for <5 s 42 
epochs (ICC=0.73), ENMO 350+ mg for 15 s epochs (ICC=0.73), ENMO 400+ mg 43 
for 60 s epochs (ICC=0.65). Agreement was robust with cross-validation ICCs=0.62-44 
0.71 and means within ׀7.8׀±4.9% of MVPA estimates from ActiGraph cut-points, 45 
except Puyau 60 s epochs (ICC=0.42). Conclusion: Incremental ENMO thresholds 46 
enable children’s acceleration data measured at the wrist to be simply and directly 47 
compared, at a group level, to past estimates of MVPA from hip-worn ActiGraphs 48 
across a range of cut-points.  49 
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 Introduction 51 
Objective measures of physical activity, specifically uniaxial hip-worn 52 
accelerometers, were introduced into national surveys in the US (National Health and 53 
Nutrition Examination Survey, NHANES) in 2003 (29), Canada (Canada Health 54 
Measures Survey) in 2007 (7,8) and the UK (Health Survey for England) in 2008 55 
(17). Also in 2008, the International Children’s Accelerometry Database (ICAD) was 56 
initiated: a compilation of accelerometer-derived estimates of children’s physical 57 
activity from a wide range of studies, settings, and countries (28).  The accelerometers 58 
employed in these surveys and studies converted accelerations into proprietary counts 59 
stored in 5-60 s epochs and time accumulated in moderate-to-vigorous physical 60 
activity (MVPA) was subsequently estimated.  61 
 62 
Over the past decade there have been rapid developments in accelerometry resulting 63 
in the commercial availability of triaxial microelectromechanical (MEMS) 64 
accelerometers that continuously sample and store raw accelerations at up to 100 Hz, 65 
such as the ActiGraph GT3X+ and the GENEActiv. There has also been a move to 24 66 
h wear protocols with wrist-wear to maximize compliance (2,9,14) and facilitate 67 
measurement of the full spectrum of physical behaviours (physical activity, sedentary 68 
behavior and sleep) (6). As a result, since 2011, wrist-worn ActiGraph GT3X+ 69 
monitors that collect and store raw accelerations at 100 Hz have been used in 70 
NHANES (30). Other large-scale adult (2,9,21) and children’s (9,10,20,34) studies 71 
are also employing 24 h wrist-worn accelerometer protocols using the GENEActiv.  72 
 73 
As the ActiGraph GT3X+ and the GENEActiv store raw accelerations rather than 74 
proprietary counts, their data should, theoretically, be comparable. Output from the 75 
 GENEActiv and the Actigraph GT3X+, when processed and calibrated identically 76 
using the open source package GGIR (32,33) in R [http:/cran.r-project.org], have high 77 
agreement for acceleration magnitudes >50-80 mg, indicative of light activity and 78 
MVPA, although not for lower acceleration magnitudes indicative of sedentary time 79 
(27). 80 
 81 
Advances in measurement methods (e.g. self-report to objective measurement) and/or 82 
measurement technologies (e.g. proprietary count uniaxial accelerometers to raw 83 
acceleration triaxial accelerometers) bring reduced bias, improved precision and 84 
enhanced measurement opportunities (30), but at a cost of limited comparability to 85 
past data. There is a wealth of MVPA data on children estimated from uniaxial hip-86 
worn ActiGraphs (28,29) and it is desirable to use these data to: contextualize future 87 
estimates of MVPA; map trends in physical activity; compare effectiveness of past 88 
and present interventions; and understand the clinical significance of intervention 89 
changes in PA, by contextualizing current data with the extant historical evidence on 90 
the impact of physical activity on health. To complicate comparisons further, hip-91 
worn ActiGraph data have been analyzed using an extensive range of cut-points 92 
leading to widely varying estimates of MVPA even for the same dataset (4,5,15).  93 
 94 
The purpose of this study is to provide a means for quickly and simply comparing raw 95 
acceleration data from wrist-worn accelerometers at a group level to past estimates of 96 
children’s MVPA from a range of cut-points applied to hip-worn ActiGraph data. To 97 
do this, we used data from three studies that have concurrent 7-day accelerometer 98 
wear at the wrist (GENEActiv) and hip (ActiGraph) to determine and cross-validate 99 
the acceleration magnitudes most closely associated with established MVPA cut-100 
 points. As the GENEActiv and ActiGraph GT3X+ have high agreement for 101 
accelerations indicative of light activity and MVPA (27), the results will be applicable 102 
to studies measuring raw triaxial accelerations at the wrist in children with either the 103 
ActiGraph GT3X+ or the GENEActiv.  104 
 105 
Methods 106 
 107 
This is a secondary data analysis using data from three studies: 1) 58 children, aged 108 
10-12 years, recruited from primary schools in South Australia (26); 2) 129 children, 109 
aged 9-10 years, recruited from primary schools in Liverpool, UK (12); 3) 81 110 
children, aged 9-11 years, recruited from one primary school in Liverpool, UK. The 111 
appropriate university research ethics committee approved each study. Written 112 
informed consent and assent were obtained from the parents/guardians and children, 113 
respectively. Height was measured to the nearest 0.1 cm and body mass to the nearest 114 
0.1 kg. 115 
 116 
Assessment of activity 117 
 118 
Free-living physical activity was measured by concurrent wear of the GENEActiv on 119 
the non-dominant wrist and the ActiGraph GT3X+ positioned above the right hip, on 120 
an elasticated belt worn around the waist, for seven consecutive days. In study 1, 121 
children were requested to wear both monitors day and night, removing the hip-worn 122 
ActiGraph for water-based activities only. In studies 2 and 3, children were requested 123 
to wear both monitors at all times except when sleeping or during water-based 124 
activities.   125 
  126 
Accelerometers 127 
 128 
The GENEActiv is a triaxial accelerometry-based activity monitor with a dynamic 129 
range of +/- 8g (Gravity Estimator of Normal Everyday Activity, ActivInsights Ltd, 130 
Cambridgeshire, UK). The ActiGraph GT3X+ is a triaxial accelerometry-based 131 
activity monitor with a dynamic range of +/- 6 g (ActiGraph LLC, Pensacola, FL, 132 
USA). Study 1: The GENEActivs were initialized to collect data at 87.5 Hz and data 133 
uploaded using GENEActiv PC software version 2.2. The ActiGraphs were initialized 134 
to collect data at 80 Hz and data uploaded using Actilife version 6.5.3. Data were 135 
collected between April and December 2012. Studies 2 and 3: The GENEActivs and 136 
ActiGraphs were both initialized to collect data at 100 Hz and data uploaded using 137 
GENEActiv PC software version 2.2 and Actilife version 6.11.4, respectively. Study 138 
2 data were collected between January and May 2014 and study 3 data were collected 139 
in January and February 2015.  140 
 141 
Data processing 142 
 143 
Wrist-worn GENEActiv (raw acceleration) GENEActiv .bin files were analysed with 144 
R-package GGIR version 1.2-0 (http://cran.r-project.org) (32,33). Signal processing in 145 
GGIR includes the following steps: 1. Autocalibration using local gravity as a 146 
reference (32); 2. Detection of sustained abnormally high values; 3. Detection of non-147 
wear; 4. Calculation of the average magnitude of dynamic acceleration, i.e. the vector 148 
magnitude of acceleration corrected for gravity (Euclidean Norm minus 1 g, ENMO) 149 
over user-defined s epochs: 150 
 ENMO   =   151 with negative values set to zero. In study 1, 
ENMO was averaged over 5 s epochs; in studies 2 and 3, ENMO was averaged over 1 152 
s epochs. As studies applying GGIR to wrist accelerometer data have used both 1 s 153 
(12) and 5 s epochs (9), inclusion of both epochs increases the generalizability of the 154 
findings. 155 
 156 
Files were excluded from all analyses if post-calibration error was greater than 0.02 g 157 
(9) and individual days were classified as invalid and excluded if wear-time was 158 
insufficient (16 h for the 24 h protocol in study 1, 10 h for the waking wear protocol 159 
in studies 2 and 3). Detection of non-wear has been described in detail previously 160 
(See ‘Procedure for non-wear detection’ in supplementary document to van Hees et 161 
al. (33)). In brief, non-wear is estimated based on the standard deviation and value 162 
range of each axis, calculated for 60 min windows with 15-min moving increments. If 163 
for at least 2 out of the 3 axes the SD is less than 13 mg or the value range is less than 164 
50 mg the time window is classified as non-wear. The default non-wear setting was 165 
used, i.e. invalid data were imputed by the average at similar timepoints on different 166 
days of the week 167 
 168 
The distribution of time spent across ENMO levels in 50 mg resolution (0-50 mg, 50-169 
100 mg….. >400 mg) was calculated using the argument ‘ilevels’ from the GGIR 170 
package. The time spent above thresholds of 100, 150, 200, 250, 300, 350 and 400 mg 171 
was calculated for comparison to widely used hip-worn ActiGraph MVPA cut-points. 172 
 173 
Hip-worn ActiGraph (counts) 174 
 175 
 Data were analyzed using Actilife version 6.13.0. The raw.gt3x files were 176 
summarized into uniaxial (vertical) proprietary counts in 1 s, 5 s, 15 s and 60 s 177 
epochs, resulting in four ActiGraph files for analysis per participant. Non-wear was 178 
defined as 60 min of consecutive zero counts, with an allowance for 1-2 min of counts 179 
between 0 and 100 (29). Individual days were classified as invalid and excluded if 180 
wear-time was insufficient (16 h for the 24 h protocol in study 1, 10 h for the waking 181 
wear protocol in studies 2 and 3).  182 
 183 
Each file was analyzed with four widely-used MVPA cut-points: very low (1100 cpm 184 
(counts per minute), approximately equivalent to the cut-point for an 11 y old (3 185 
METs) using the age-specific criteria of the Freedson group, published by Trost et al. 186 
(31)); low (1680 cpm, Pate et al. (23)); medium (2296 cpm, Evenson et al. (11)); high 187 
(3200 cpm, Puyau et al. (24)). This resulted in 16 outputs per participant: MVPA 188 
classified using very low, low, medium and high cut-points, with each cut-point 189 
applied to data integrated into 1 s, 5 s, 15 s and 60 s epochs. 190 
 191 
Data analysis 192 
 193 
For each participant, days were only included if classified as valid for both the wrist-194 
worn GENEActiv and hip-worn ActiGraph; therefore to be included a participant 195 
needed a minimum of one day where both the ActiGraph and GENEActiv recorded 196 
sufficient wear time. The daily means for all output variables were taken for each 197 
participant. For data from study 1, GENEActiv 5 s epoch outputs were compared to 198 
the ActiGraph 5 s, 15 s and 60 s epoch outputs. For data from studies 2 and 3, the 199 
GENEActiv 1 s epoch files were compared to the ActiGraph 1 s, 15 s and 60 s 200 
 epochs. The 5 s data from study 1 and the 1 s data from studies 2 and 3 were 201 
designated a <5 s epoch. 202 
 203 
Descriptive statistics (mean ± SD) were calculated for all variables. Data from studies 204 
1 and 2 (approximately 70% of the total sample) were analyzed with data from study 205 
3 reserved for cross validation. The wrist-worn GENEActiv ENMO thresholds (100+, 206 
150 +, 200+, 250+, 300+, 350+, 400+ mg) which most closely approximated time 207 
accumulated in each of the hip-worn ActiGraph MVPA cut-points (very low, low, 208 
medium, high) for each epoch length (<5 s, 15 s, 60 s) were examined with a series of 209 
limits of agreement (LoA) analyses (3) and intra-class correlations (ICC, single 210 
measures, absolute agreement) with 95% confidence intervals (CI).  211 
 212 
For each hip-worn ActiGraph MVPA cut-point / epoch combination, the wrist-worn 213 
ENMO threshold with the closest agreement was selected and the agreement between 214 
these optimal pairings tested in the independent cross-validation sample. The 215 
distributions for each of the optimal pairings were illustrated on kernel density plots 216 
(bandwidth = 10) for the total sample (data from studies 1, 2 and 3 combined). 217 
 218 
Results 219 
 220 
Demographic data, by study, are presented in Table 1. The final sample size was 238 221 
(Test sample N = 159, Cross-validation sample N = 79) with 30 participants excluded 222 
due to no days of concurrent valid wear for both monitors. Figure 1 shows the time 223 
recorded in each of the intensity categories by the hip-worn ActiGraph (very low, 224 
low, medium and high MVPA cut-points) and the wrist-worn GENEActiv (100+, 225 
 150+, 200+, 250+, 300+, 350+, 400+ mg ENMO thresholds) by epoch (ActiGraph <5 226 
s, 15 s, 60 s; GENEActiv <5s) for the total sample. 227 
 228 
Test sample 229 
 230 
The agreement between each wrist-worn GENEActiv ENMO threshold and each hip-231 
worn ActiGraph MVPA cut-point is shown for each epoch length in Table 2. The 232 
ENMO threshold with the highest agreement for each ActiGraph MVPA cut-point / 233 
epoch combination is highlighted in bold in Table 2. The optimal wrist-worn ENMO 234 
thresholds for comparison to hip-worn ActiGraph MVPA cut-points were: 235 
 very low MVPA ActiGraph cut-points (1100 cpm, Trost et al. (31))   236 
o ENMO 150+ mg, irrespective of the ActiGraph epoch (ICC > 0.65, 237 
mean bias (ENMO – ActiGraph) = -2.9 to -18.0 min, (-2.7 to -14.9% 238 
of mean MVPA));  239 
 low MVPA ActiGraph cut-points (1680 cpm, Pate et al. (23))  240 
o ENMO 200+ mg, irrespective of the ActiGraph epoch (ICC > 0.67, 241 
mean bias = -4.1 to -10.7 min (-5.4 to -13.0% of mean MVPA)); 242 
 medium MVPA cut-points (2296 cpm, Evenson et al. (11))  243 
o ENMO 250+ mg for <5 s and 15 s epochs (ICC > 0.69, mean bias = -244 
3.0 to -7.3 min (-5.4 to -12.0% of mean MVPA))  245 
o ENMO 300+ mg for 60 s epochs (ICC = 0.73, mean bias = -5.0 min (-246 
10.6% of mean MVPA)); 247 
 high MVPA cut-points (3200 cpm, Puyau et al. (24))  248 
o ENMO 300+ mg for <5 s epochs (ICC = 0.73, mean bias = +1.8 min 249 
(+4.7% of mean MVPA)) 250 
 o ENMO 350+ mg for 15 s epochs (ICC = 0.73, mean bias = +2.7 min 251 
(+8.7% of mean MVPA))  252 
o ENMO 400+ mg for 60 s epochs (ICC = 0.65, mean bias = +6.5 min 253 
(+28.6% of mean MVPA)). 254 
 255 
Cross-validation 256 
 257 
The agreement of each of these optimal pairings of wrist-worn ENMO threshold and 258 
hip-worn ActiGraph MVPA cut-point was tested in the cross-validation sample 259 
(Table 3, Figure 2). Agreement was robust with ICC’s similar to the test sample for 260 
15 s epochs (very low, low and medium MVPA cut-points, mean bias = ׀4.9׀ ± 0.9% 261 
of mean MVPA) and ≈0.01-0.11 lower than the test sample (0.61 to 0.71, mean bias = 262 
׀8.9׀ ± 4.8% of mean MVPA) for other MVPA cut-point / epoch combinations, except 263 
for the high MVPA cut-point / 60 s epoch where the ICC was considerably reduced 264 
(0.42). The mean biases and 95% limits of agreement were also similar in magnitude 265 
to the test sample. However, the values of the mean bias for specific pairings were not 266 
consistent between the test sample and the cross-validation sample.  267 
 268 
The distribution of the ActiGraph and ENMO data for each of the optimal pairings is 269 
shown on kernel density plots for the total sample, Figure 3. The columns represent 270 
cut-points (left to right: very low, low, medium, high) and the rows represent 271 
ActiGraph epochs (top to bottom: <5 s, 15 s, 60 s). The agreement statistics for the 272 
total sample are shown in Supplemental Digital Content 1. 273 
 274 
 275 
  276 
 277 
Discussion  278 
 279 
Rapid progress in accelerometer technology has led to changes in the data collected 280 
and study protocols followed, with a shift from uniaxial proprietary count outcomes 281 
collected using accelerometers worn at the hip to triaxial raw accelerations measured 282 
using wrist-worn accelerometers (30). We have developed a quick and simple method 283 
to facilitate the comparison of group level estimates of children’s MVPA from 284 
uniaxial hip-worn count-based ActiGraphs to triaxial raw acceleration data measured 285 
at the wrist processed using the open source R-package, GGIR (32,33). The method 286 
was developed using the GENEActiv wrist-worn accelerometer, but evidence 287 
suggests it will also be applicable to raw acceleration measured at the wrist using the 288 
ActiGraph and processed in GGIR (27).  289 
 290 
Mean biases for optimal pairings of ENMO thresholds and ActiGraph MVPA cut-291 
points were relatively low (test sample: mean bias = ׀9.4׀ ± 4.2% of mean MVPA; 292 
cross-validation sample: mean bias = ׀7.8׀ ± 4.9% of mean MVPA) indicating good 293 
group level agreement, excluding high ActiGraph MVPA cut-points assessed using a 294 
60 s epoch where mean bias was high relative to the low means (29% in the test 295 
sample, 60% in the cross-validation sample). Similarly, the ICC’s for optimal pairings 296 
were all between 0.61 and 0.76 in the test and cross-validation sample, indicating 297 
good agreement (13), with the exception of the high ActiGraph MVPA cut-points 298 
assessed using a 60 s epoch in the cross-validation sample (ICC = 0.42). The 95% 299 
limits of agreement were moderate to large indicating that individual level 300 
 comparisons are not advised. The MVPA recorded in the cross-validation sample was 301 
lower than the test samples, in particular when applying high cut-points with a 60 s 302 
epoch (Figures 1 and 2); this may have contributed to the lower robustness for the 303 
high cut-point/60 s epoch combination. Hildebrand et al. (16) developed an MVPA 304 
threshold of approximately 200 mg for use with wrist-worn ActiGraph and 305 
GENEActiv accelerometers. Based on the current findings, MVPA determined by 306 
applying the 200 mg threshold to wrist-worn accelerometer data should compare best 307 
to MVPA determined from low cut-points (23) applied to hip-worn ActiGraph data, 308 
irrespective of epoch. Overall, the cross-validation suggests that agreement may be 309 
closest when comparing ENMO 150+, 200+ and 250+ thresholds to MVPA estimated 310 
from ActiGraph 15 s epoch data processed using very low, low and medium cut-311 
points, respectively. 312 
 313 
The potential for application of these comparisons is extensive. By 2010, over 46000 314 
physical activity datasets from hip-worn ActiGraphs had been collated in the ICAD, 315 
approximately 19000 from children aged 9-12 y, (28). More recently, the 316 
International Study of Childhood Obesity, Lifestyle and the Environment (ISCOLE) 317 
collected data on 6000 children, aged 9-11 y from 12 countries across five diverse 318 
regions of the world using hip-worn ActiGraphs (18). The latter study collected 319 
triaxial raw acceleration data using ActiGraph GT3X+ and has developed novel 320 
analytical tools for application to the raw acceleration data, e.g. to determine sleep 321 
duration (1), but as the hip was the measurement site these data have also been 322 
summarized in proprietary counts and analyzed using count cut-points (19).  Since 323 
NHANES moved to assessing physical activity using triaxial raw acceleration data 324 
measured at the wrist for the NHANES cycles 2011-2012 and 2013-2014 (30), many 325 
 other large studies have also used wrist-worn accelerometers. For example, data have 326 
already been collected in: ≈4000 children, aged 9-11 y, in the Child Health 327 
Checkpoint (Melbourne, Australia (34)); ≈1800 girls, aged 11-14 y, in Girls Active 328 
(Leicester, UK (10));  ≈1000 children, aged 8-11 y in the Cork Children’s Lifestyle 329 
Study (Ireland (20)); and ≈4000 children aged 7 y in the Pelotas Birth cohort (Brazil 330 
(9)). The comparisons presented will facilitate interpretation of these data in relation 331 
to past estimates of children’s MVPA, e.g. from NHANES, ICAD and ISCOLE.  332 
 333 
The data collated for this study came from three different sources and were collected 334 
using two differing protocols. Study 1 took place in South Australia, used a 24 h wear 335 
protocol and summarized the GENEActiv ENMO data in 5 s epochs. Studies 2 and 3 336 
took place in the UK, used a waking time only protocol and summarized the ENMO 337 
data in 1 s epochs. While the results were similar across studies and the cross-338 
validation (study 3 data) showed the agreement statistics were robust, these 339 
differences limit the internal validity of the study. However, the external validity is 340 
enhanced, as results are applicable to ENMO data collected in 1 s and 5 s epochs 341 
using either a waking or 24 h protocol. Given the outcome of interest was MVPA it is 342 
not surprising that the use of a waking or 24 h protocol did not impact on the results.  343 
 344 
ActiGraph epochs of <5 s, 15 s and 60 s were considered, whereas ENMO data were 345 
only summarized into <5 s epochs. The use of longer epochs in the past was due to 346 
the memory limitations of accelerometers (30). Accelerations were integrated onboard 347 
the accelerometer and stored in epochs, normally 60 s epochs, to ensure one week of 348 
data could be stored before downloading the data. Due to technological progress 349 
onboard memory is no longer a problem and raw acceleration data collected at 100 Hz 350 
 can be stored for one week. Therefore it is unlikely that epochs longer than the default 351 
5 s epoch in GGIR will be used, particularly when assessing children’s activity where 352 
the typical sporadic activity patterns are best captured using short epochs (22). It 353 
should be noted that the participants in this study were from a relatively narrow age 354 
range and the results cannot be generalized beyond the 9-12 y age group tested. 355 
 356 
In summary, this study indicates that, in 9-12 y old children, time accumulated above 357 
the appropriate incremental ENMO threshold has good agreement at a group level 358 
with a range of widely used very low to high ActiGraph MVPA cut-points. It is 359 
important to note this is a simple pooled-data comparison study that enables group 360 
level comparisons, but individual level comparisons are not advised.  We recommend 361 
that when processing triaxial raw acceleration wrist accelerometer data using GGIR, 362 
the times accumulated above ENMO thresholds ranging from >100 to >400 mg, or in 363 
incremental acceleration bins (e.g. 9), are presented. As well as providing an activity 364 
profile, this will enable the reader to quickly and simply compare the findings to past 365 
estimates of children’s MVPA from hip-worn ActiGraph data across a range of 366 
widely used cut-points.  367 
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 Figure legends 497 
Figure 1. Time recorded above each of the intensity thresholds by the hip-worn 498 
ActiGraph (very low, low, medium and high MVPA count cut-points) and the wrist-499 
worn GENEActiv (100+, 150+, 200+, 250+, 300+, 350+, 400+ mg ENMO 500 
thresholds) by epoch (ActiGraph <5 s, 15 s, 60 s; GENEActiv <5s) for the total 501 
sample. Boxplot shows the median (dark line), 25th and 75th percentiles (box), lowest 502 
and highest values within 1.5 times the inter-quartile range (whiskers) and outliers 503 
(circles). 504 
 505 
Figure 2. The time recorded above each of the intensity thresholds by the hip-worn 506 
ActiGraph (very low (a), low (b), medium (c) and high (d) MVPA count cut-points) 507 
and the wrist-worn GENEActiv acceleration threshold by epoch (ActiGraph <5 s, 15 508 
s, 60 s; GENEActiv <5s) for each of the optimal pairings in the cross-validation 509 
sample. Boxplots show the median (dark line), 25th and 75th percentiles (box), lowest 510 
and highest values within 1.5 times the inter-quartile range (whiskers) and outliers 511 
(circles). 512 
 513 
Figure 3. Kernel density plots showing the distribution of time recorded above each of 514 
the intensity thresholds by the hip-worn ActiGraph and the wrist-worn GENEActiv 515 
for each of the optimal pairings (total sample). The columns represent cut-points (left 516 
to right: very low, low, medium, high) and the rows represent ActiGraph epochs (top 517 
to bottom: <5 s, 15 s, 60 s) 518 
 519 
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 Table 1. Participant characteristics (mean ± standard deviation (SD))   522 
Study Valid N  
(boys) 
Age (y) Height (cm) Mass (kg) 
1 51 (26) 11.3 ± 0.6 148.7 ± 6.8 44.1 ± 11.2 
2 108 (42) 10.0 ± 0.3 139.1 ± 7.6 35.4 ± 8.5 
1 & 2 (Test sample) 159 (68) 10.4 ± 0.7 142.2 ± 8.6 38.3 ± 10.3 
3 (Cross-validation sample) 79 (5) 10.3 ± 0.6 142.1 ± 7.8 36.9 ± 8.6 
Total sample 238 (103) 10.4 ± 0.7 142.2 ± 8.3 37.8 ± 9.7 
523 
 Table 2. Agreement between each hip-worn ActiGraph cut-point and each wrist-worn GENEActiv ENMO threshold by epoch length in the test sample 524 
(N=159) 525 
 HIP WRIST ActiGraph <5 s epoch ActiGraph 15 s epoch 
 
ActiGraph 60 s epoch 
ActiGraph 
cut-point 
 
GENEActiv 
ENMOe   
(mg) 
ICCf 
(95% CIg) 
Mean bias 
(G-AG, min) 
95% LoAh 
(+/- min) 
ICCf 
(95% CIg) 
Mean bias 
(G-AG, min) 
95% LoAg 
(+/- min) 
 
ICCf 
(95% CIg) 
Mean bias 
(G-AG, min) 
95% LoAh 
(+/- min) 
Very lowa 100+ 0.29  
(-0.09, 0.62) 
55.9 59.6 0.43  
(-0.10, 0.72) 
42.8 58.7 0.47  
(-0.08, 0.75) 
40.7 61.6 
 150+ 0.71  
(0.62, 0.78) 
-2.9 43.9 0.67  
(0.33, 0.82) 
-15.9 44.1 0.65  
(0.31, 0.81) 
-18.0 49.5 
 200+ 0.36  
(-0.10, 0.69) 
-34.6 39.6 0.30  
(-0.08, 0.65) 
-47.7 41.8 0.31  
(-0.09, 0.65) 
-49.8 49.4 
 250+ 0.18  
(-0.06, 0.49) 
-53.0 39.4 0.16  
(-0.05, 0.46) 
-66.0 43.4 0.18  
(-0.06, 0.48) 
-68.1 52.2 
 300+ 0.11  
(-0.04, 0.36) 
-64.3 40.0 0.10  
(-0.04, 0.35) 
-77.3 45.3 0.12  
(-0.05, 0.37) 
-79.4 54.9 
 350+ 0.08  
(-0.03, 0.28) 
-71.8 40.8 0.08  
(-0.03, 0.28) 
-84.9 47.1 0.09  
(-0.04, 0.30) 
-87.0 57.1 
 400+ 0.06 
 (-0.03, 0.23) 
-77.2 41.7 0.06  
(-0.03, 0.23) 
-90.3 48.7 0.07  
(-0.04, 0.24) 
-92.4 59.0 
Lowb 100+ 0.16  
(-0.06, 0.44) 
80.4 61.6 0.18 
(-0.06, 0.49) 
79.8 60.9 0.17  
(-0.06, 0.47) 
86.4 63.0 
 150+ 0.53  
(0.01, 0.77) 
21.6 41.2 0.59  
(0.05, 0.81) 
21.0 40.6 0.53  
(-0.07, 0.79) 
27.6 42.7 
 200+ 0.67  
(0.41, 0.80) 
-10.1 32.7 0.71  
(0.44, 0.83) 
-10.7 33.5 0.75  
(0.67, 0.81) 
-4.1 36.4 
 250+ 0.37  
(-0.09, 0.70) 
-28.5 30.1 0.41  
(-0.10, 0.73) 
-29.1 32.5 0.51  
(-0.06, 0.77) 
-22.5 36.1 
 300+ 0.22  
(-0.06, 0.55) 
-39.8 29.6 0.25  
(-0.07, 0.59) 
-40.4 33.3 0.33  
(-0.10, 0.66) 
-33.8 37.5 
 350+ 0.15  
(-0.04, 0.44) 
-47.3 29.9 0.18  
(-0.06, 0.49) 
-47.9 34.5 0.23  
(-0.08, 0.56) 
-41.3 39.0 
  400+ 0.11  
(-0.04, 0.36) 
-52.7 30.6 0.13  
(-0.05, 0.41) 
-53.3 35.9 0.18  
(-0.07, 0.47) 
-46.7 40.5 
Mediumc 100+ 0.09  
(-0.04, 0.29) 
101.6 65.9 0.09 
(-0.04, 0.31) 
105.8 65.5 0.08  
(-0.04, 0.28) 
115.2 66.9 
 150+ 0.26  
(-0.09, 0.59) 
42.8 43.1 0.27  
(-0.08, 0.60) 
47.1 42.2 0.21  
(-0.06, 0.54) 
56.4 43.3 
 200+ 0.63  
(0.30, 0.79) 
11.1 31.7 0.61  
(0.09, 0.82) 
15.3 31.1 0.48  
(-0.10, 0.77) 
24.7 32.0 
 250+ 0.69  
(0.48, 0.80) 
-7.3 26.4 0.76  
(0.69, 0.82) 
-3.0 26.7 0.73  
(0.59, 0.82) 
6.4 27.7 
 300+ 0.46  
(-0.10, 0.76) 
-18.6 24.3 0.58  
(0.00, 0.81) 
-14.4 25.6 0.73  
(0.61, 0.81) 
-5.0 26.6 
 350+ 0.30  
(-0.08, 0.65) 
-26.1 23.6 0.41  
(-0.10, 0.73) 
-21.9 25.7 0.58  
(0.10, 0.79) 
-12.5 26.9 
 400+ 0.22  
(-0.06, 0.55) 
-31.5 23.6 0.30  
(-0.08, 0.64) 
-27.3 26.4 0.45  
(-0.08, 0.73) 
-17.9 27.6 
Highd 100+ 0.05  
(-0.03, 0.17) 
122.0 71.3 0.04  
(-0.03, 0.16) 
130.4 72.1 0.03  
(-0.02, 0.13) 
139.5 73.9 
 150+ 0.12  
(-0.05, 0.37) 
63.3 47.1 0.10  
(-0.05, 0.33) 
71.7 47.8 0.07  
(-0.04, 0.27) 
80.7 49.6 
 200+ 0.28  
(-0.09, 0.61) 
31.6 33.4 0.21  
(-0.07, 0.54) 
40.0 34.1 0.15  
(-0.05, 0.43) 
49.0 35.6 
 250+ 0.54  
(0.03, 0.77) 
13.2 25.7 0.40  
(-0.10, 0.71) 
21.6 27.3 0.26  
(-0.08, 0.59) 
30.7 27.6 
 300+ 0.73  
(0.65, 0.80) 
1.8 21.5 0.60  
(0.12, 0.80) 
10.3 22.3 0.40  
(-0.10, 0.71) 
19.3 23.2 
 350+ 0.69  
(0.46, 0.81) 
-5.7 19.3 0.73  
(0.64, 0.80) 
2.7 20.2 0.54  
(-0.02, 0.78) 
11.8 20.8 
 400+ 0.55  
(-0.04, 0.80) 
-11.1 18.3 0.72  
(0.64, 0.80) 
-2.6 19.2 0.65  
(0.36, 0.79) 
 
6.5 19.5 
aVery low  = 1100 cpm, approximately equivalent to the 3 MET cut-point, age 11 y, age-specific criteria of the Freedson group, published by Trost et al. (31) 526 
bLow   = 1680 cpm, Pate et al. (23) 527 
 cMedium  = 2296 cpm, Evenson et al. (11) 528 
dHigh   = 3200 cpm, Puyau et al. (24) 529 
eENMO = Euclidean Norm Minus One, the vector magnitude of acceleration corrected for gravity 530 
fICC  = Intra-class correlation coefficient 531 
g95% CI = 95% confidence interval 532 
hLoA  = Limits of agreement 533 
The ENMO threshold with the highest agreement for each ActiGraph count cut-point / epoch combination is highlighted in bold. 534 
  535 
 Table 3. Cross-validation sample: Agreement between the hip-worn ActiGraph and wrist-worn GENEActiv for the optimal ENMO threshold for each 536 
ActiGraph count cut-point / epoch combination (N = 79) 537 
 GENEActiv ActiGraph <5 s epoch ActiGraph 15 s epoch 
 
ActiGraph 60 s epoch 
ActiGraph 
cut-point 
HIP 
ENMOe   
(mg) 
WRIST 
ICCf 
(95% CIg) 
Mean bias 
(G-AG, min) 
95% LoAh 
(+/- min) 
ICCf 
(95% CIg) 
Mean bias 
(G-AG, min) 
95% LoAg 
(+/- min) 
 
ICCf 
(95% CIg) 
Mean bias 
(G-AG, 
min) 
95% LoAh 
(+/- min) 
Very lowa 150+ 0.63  
(0.46, 0.75) 
7.0 39.4 0.71  
(0.57, 0.80) 
-5.9 39.1 0.69  
(0.55, 0.80) 
-6.2 42.6 
Lowb 200+ 0.66  
(0.51, 0.77) 
-3.8 31.0 0.71  
(0.58, 0.80) 
-3.0 31.2 0.69  
(0.55, 0.80) 
5.3 32.8 
Mediumc 250+ 0.64  
(0.49, 0.76) 
-3.6 25.7 0.70  
(0.57, 0.80) 
2.0 13.1    
 300+       0.69  
(0.56, 0.79) 
2.2 23.8 
Highd 300+ 0.62  
(0.46, 0.74) 
2.7 21.5       
 350+    0.61  
(0.33, 0.76) 
5.5 18.7    
 400+       0.42  
(-0.04, 0.69) 
9.7 18.2 
 538 
aVery low  = 1100 cpm, approximately equivalent to the 3 MET cut-point, age 11 y, age-specific criteria of the Freedson group, published by Trost et al. (31) 539 
bLow   = 1680 cpm, Pate et al. (23) 540 
cMedium  = 2296 cpm, Evenson et al. (11) 541 
dHigh   = 3200 cpm, Puyau et al. (24) 542 
eENMO = Euclidean Norm Minus One, the vector magnitude of acceleration corrected for gravity 543 
fICC  = Intra-class correlation coefficient 544 
g95% CI = 95% confidence interval 545 
hLoA  = Limits of agreement 546 
 547 
 Supplementary Table. Agreement between each hip-worn ActiGraph cut-point and each wrist-worn GENEActiv ENMO threshold by epoch length in 548 
the total sample (N = 238) 549 
 HIP WRIST ActiGraph <5 s epoch ActiGraph 15 s epoch 
 
ActiGraph 60 s epoch 
ActiGraph 
cut-point 
 
GENEActiv 
ENMOe 
(mg) 
ICCf 
(95% CIg) 
Mean bias 
(G-AG, min) 
95% LoAh 
(+/- min) 
ICCf 
(95% CIg) 
Mean bias 
(G-AG, min) 
95% LoAg 
(+/- min) 
 
ICCf 
(95% CIg) 
Mean bias 
(G-AG, 
min) 
95% 
LoAh (+/- 
min) 
Very lowa 100+ 0.27  
(-0.09, 0.60) 
57.5 59.6 0.36  
(-0.10, 0.68) 
44.5 57.1 0.44  
(-0.09, 0.73) 
43.0 59.6 
 150+ 0.70  
(0.63, 0.76) 
0.4 43.4 0.68  
(0.57, 0.76) 
-12.6 43.4 0.67  
(0.45, 0.79) 
-14.1 48.5 
 200+ 0.39  
(-0.10, 0.70) 
-30.5 38.6 0.34  
(-0.10, 0.66) 
-43.5 40.9 0.33  
(-0.09, 0.66) 
-45.0 48.0 
 250+ 0.19  
(-0.06, 0.51) 
-48.4 38.0 0.18  
(-0.06, 0.48) 
-61.4 42.2 0.18  
(-0.06, 0.49) 
-62.9 50.4 
 300+ 0.12  
(-0.04, 0.39) 
-59.4 38.5 0.12  
(-0.05, 0.37) 
-72.4 44.0 0.12  
(-0.05, 0.37) 
-73.9 52.8 
 350+ 0.09  
(-0.04, 0.29) 
-66.8 39.3 0.08  
(-0.04, 0.29) 
-79.8 45.7 0.09  
(-0.04, 0.30) 
-81.3 54.8 
 400+ 0.064 
 (-0.03, 0.24) 
-72.0 40.2 0.07  
(-0.04, 0.24) 
-85.0 47.3 0.07  
(-0.04, 0.25) 
-86.5 56.6 
Lowb 100+ 0.15  
(-0.06, 0.43) 
79.9 80.0 0.16 
(-0.06, 0.46) 
79.9 59.5 0.16  
(-0.05, 0.45) 
87.1 61.1 
 150+ 0.50  
(-0.02, 0.75) 
22.9 41.1 0.54  
(-0.01, 0.78) 
22.8 40.5 0.48  
(-0.09, 0.76) 
29.9 42.6 
 200+ 0.68  
(0.51, 0.78) 
-8.0 32.7 0.71  
(0.54, 0.80) 
-8.2 33.4 0.74  
(0.68, 0.80) 
-1.0 36.3 
 250+ 0.39  
(-0.10, 0.71) 
-25.9 29.7 0.42  
(-0.10, 0.73) 
-26.0 32.1 0.54  
(0.01, 0.77) 
-18.9 35.6 
 300+ 0.23  
(-0.06, 0.56) 
-36.9 29.0 0.25  
(-0.07, 0.59) 
-37.1 32.6 0.35  
(-0.10, 0.67) 
-29.9 36.6 
 350+ 0.15  
(-0.05, 0.45) 
-44.3 29.2 0.18  
(-0.06, 0.48) 
-44.4 33.7 
 
0.25  
(-0.09, 0.57) 
-37.3 37.9 
  400+ 0.11  
(-0.04, 0.37) 
-49.5 29.7 0.13  
(-0.05, 0.40) 
-49.7 34.9 0.19  
(-0.08, 0.49) 
-42.5 39.3 
Mediumc 100+ 0.08  
(-0.04, 0.28) 
99.9 66.1 0.08 
(-0.04, 0.29) 
104.6 64.0 0.07  
(-0.03, 0.26) 
114.4 65.5 
 150+ 0.25  
(-0.09, 0.57) 
42.8 42.9 0.25  
(-0.08, 0.58) 
47.4 42.1 0.19  
(-0.06, 0.51) 
57.3 43.4 
 200+ 0.60  
(0.25, 0.77) 
11.8 31.7 0.59  
(0.10, 0.79) 
16.5 33.4 0.43  
(-0.10, 0.74) 
26.3 32.5 
 250+ 0.68  
(0.53, 0.78) 
-6.1 26.4 0.74  
(0.67, 0.79) 
-1.4 26.7 0.69  
(0.45, 0.81) 
8.5 27.9 
 300+ 0.47  
(-0.09, 0.75) 
-17.1 24.0 0.55  
(-0.02, 0.79) 
-12.4 25.3 0.73  
(0.66, 0.78) 
-2.6 26.5 
 350+ 0.31  
(-0.08, 0.65) 
-24.5 23.2 0.38  
(0.10, 0.71) 
-19.8 25.2 0.61  
(0.25, 0.78) 
-9.9 26.5 
 400+ 0.22  
(-0.06, 0.55) 
-29.7 23.1 0.28  
(-0.08, 0.61) 
-24.9 25.7 0.48  
(-0.03, 0.73) 
-15.2 27.0 
Highd 100+ 0.04  
(-0.03, 0.17) 
119.1 71.4 0.04  
(-0.03, 0.15) 
128.0 70.5 0.03  
(-0.02, 0.12) 
137.1 72.7 
 150+ 0.11  
(-0.05, 0.36) 
62.0 46.5 0.10  
(-0.05, 0.31) 
70.9 47.3 0.07  
(-0.04, 0.24) 
79.9 49.5 
 200+ 0.26  
(-0.09, 0.58) 
31.1 33.3 0.21  
(-0.08, 0.52) 
39.9 33.4 0.13  
(-0.05, 0.40) 
49.0 36.0 
 250+ 0.51  
(0.02, 0.75) 
13.2 25.7 0.40  
(-0.09, 0.69) 
22.1 26.3 0.23  
(-0.08, 0.55) 
31.1 28.0 
 300+ 0.71  
(0.64, 0.77) 
2.1 21.5 0.60  
(0.30, 0.76) 
11.0 22.1 0.35  
(-0.10, 0.67) 
20.1 23.4 
 350+ 0.68  
(0.48, 0.79) 
-5.2 19.2 0.70  
(0.63, 0.76) 
3.7 19.9 0.48  
(-0.06, 0.75) 
12.7 20.8 
 400+ 0.54  
(-0.03, 0.78) 
-10.5 18.1 0.65  
(0.48, 0.76) 
-1.6 18.7 0.59  
(0.22, 0.36) 
 
7.5 19.3 
aVery low  = 1100 cpm, approximately equivalent to the 3 MET cut-point, age 11 y, age-specific criteria of the Freedson group, published by Trost et al. (31) 550 
bLow   = 1680 cpm, Pate et al. (23) 551 
 cMedium  = 2296 cpm, Evenson et al. (11) 552 
dHigh   = 3200 cpm, Puyau et al. (24) 553 
eENMO = Euclidean Norm Minus One, the vector magnitude of acceleration corrected for gravity 554 
fICC  = Intra-class correlation coefficient 555 
g95% CI = 95% confidence interval 556 
hLoA  = Limits of agreement 557 
The ENMO threshold with the highest agreement for each ActiGraph count cut-point / epoch combination in the test sample is highlighted in bold. 558 
 559 
560 
  561 
  562 
  563 
